Literature DB >> 32448013

Genetic Regulation of Redox Balance in β-Thalassemia Trait.

Magdalena M Terán1,2, Maria E Mónaco1,3, Sandra S Lazarte1, Cecilia Haro1,2, Emilse Ledesma Achem1, Natalia A Asensio1, Blanca A Issé1.   

Abstract

β-Thalassemia (β-thal) trait is a heterogeneous group of genetic defects leading to decreased β-globin production, ineffective erythropoiesis, and oxidative stress. The aim is to evaluate the cytoprotective response, at transcriptional and systemic levels, of the variations of global redox balance in β-thal trait patients. Sixty-six subjects (40 healthy and 26 with β-thal trait) were analyzed at the Universidad Nacional de Tucumán, Tucumán, Argentina, between 2016 and 2017. The following parameters were evaluated: complete blood count, iron status, hemoglobin (Hb) electrophoresis, Hb A2, thiobarbituric acid reactive species (TBARS), serum catalase (CAT), and superoxide dismutase (SOD) activity, FOXO3a, NRF2, SOD, PRDX2, CAT, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) gene expression. The β-thal trait group showed a decrease in Hb levels, MCV, and MCH with higher TBARS levels. The SOD activity was significantly increased by 32.0% in β-thal trait patients respect to the control group. Relative expression of NRF2 was 4.7-fold higher in β-thal trait than in the control group, while FOXO3a expression was similar in both groups. The SOD, PRDX2, and proinflammatory cytokines transcriptional expression was significantly upregulated in β-thal trait patients. This is the first study on the genetic regulation of redox balance in β-thal trait patients in which interesting modifications were observed in the transcript levels of some redox regulators that could be associated with changes in the erythrocyte proteome in this disorder. A better understanding of the pathophysiological mechanisms present in these heterozygous patients would allow adequate therapy in situations such as growth, pregnancy, or high performance sports, favoring a personalized treatment.

Entities:  

Keywords:  NRF2; oxidative stress; proinflammatory cytokines; β-Thalassemia (β-thal) trait

Mesh:

Substances:

Year:  2020        PMID: 32448013     DOI: 10.1080/03630269.2020.1765794

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  4 in total

1.  Innate Variability in Physiological and Omics Aspects of the Beta Thalassemia Trait-Specific Donor Variation Effects.

Authors:  Alkmini T Anastasiadi; Vassilis L Tzounakas; Monika Dzieciatkowska; Vasiliki-Zoi Arvaniti; Effie G Papageorgiou; Issidora S Papassideri; Konstantinos Stamoulis; Angelo D'Alessandro; Anastasios G Kriebardis; Marianna H Antonelou
Journal:  Front Physiol       Date:  2022-06-08       Impact factor: 4.755

2.  The Post-Storage Performance of RBCs from Beta-Thalassemia Trait Donors Is Related to Their Storability Profile.

Authors:  Alkmini T Anastasiadi; Efthymios C Paronis; Vasiliki-Zoi Arvaniti; Athanasios D Velentzas; Anastasia C Apostolidou; Evangelos G Balafas; Monika Dzieciatkowska; Nikolaos G Kostomitsopoulos; Konstantinos Stamoulis; Issidora S Papassideri; Angelo D'Alessandro; Anastasios G Kriebardis; Marianna H Antonelou; Vassilis L Tzounakas
Journal:  Int J Mol Sci       Date:  2021-11-13       Impact factor: 5.923

3.  Proteome of Stored RBC Membrane and Vesicles from Heterozygous Beta Thalassemia Donors.

Authors:  Vassilis L Tzounakas; Alkmini T Anastasiadi; Monika Dzieciatkowska; Dimitrios G Karadimas; Konstantinos Stamoulis; Issidora S Papassideri; Kirk C Hansen; Angelo D'Alessandro; Anastasios G Kriebardis; Marianna H Antonelou
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

4.  Beta thalassemia minor is a beneficial determinant of red blood cell storage lesion.

Authors:  Vassilis L Tzounakas; Alkmini T Anastasiadi; Davide Stefanoni; Francesca Cendali; Lorenzo Bertolone; Fabia Gamboni; Monika Dzieciatkowska; Pantelis Rousakis; Athina Vergaki; Vassilis Soulakis; Ourania E Tsitsilonis; Konstantinos Stamoulis; Issidora S Papassideri; Anastasios G Kriebardis; Angelo D'Alessandro; Marianna H Antonelou
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.